Changes in Characteristics of Men with Lethal Prostate Cancer During the Past 25 Years: Description of Population-based Deaths.
Diagnostic characteristics
Mortality
Prevalence
Prostate cancer
Journal
European urology open science
ISSN: 2666-1683
Titre abrégé: Eur Urol Open Sci
Pays: Netherlands
ID NLM: 101771568
Informations de publication
Date de publication:
Jul 2022
Jul 2022
Historique:
accepted:
06
05
2022
entrez:
11
7
2022
pubmed:
12
7
2022
medline:
12
7
2022
Statut:
epublish
Résumé
Attempts to reduce prostate cancer (PC) mortality require an understanding of temporal changes in the characteristics of men with lethal PC. To describe the diagnostic characteristics of and time trends for a nationwide population-based cohort of Swedish men who died from PC between 1992 and 2016. Men with PC as the underlying cause of death from 1992 to 2016 according to the Swedish Cause of Death Register were included in the study. Characteristics at diagnosis were collected via links to other nationwide registries using personal identity numbers. Data on disease duration, age at death, and risk category were analyzed. Missing data for risk categories for men with an early date of PC diagnosis were imputed according to the method of chained equations. Between 1992 and 2016, age-standardized PC mortality decreased by 25%. Median PC disease duration increased from 3.3 yr (interquartile range [IQR] 1.6-6.3) to 5.9 yr (IQR 2.5-10.3) and the median age at death from PC increased from 78.9 yr (IQR 73.3-84.2) to 82.2 yr (IQR 75.2-87.5). The proportion of men with localized disease at diagnosis who died from PC increased from 34% to 48%, while the rate of distant metastases at diagnosis decreased from 56% to 42%. The rate of distant metastases at diagnosis was highest among the youngest men. Treatment trajectories could not be described owing to the large proportion of missing data before the start of registration in the National Prostate Cancer Registry. Age-standardized PC mortality has decreased substantially since 1992. However, there is still a high proportion of men who die from PC who had localized disease at diagnosis, which indicates that more attention is needed to identify the underlying causes to prevent disease progression. Since the proportion of men with distant metastases at diagnosis remains high, early detection of lethal tumors is essential to further reduce PC mortality. We investigated the characteristics of men who died from prostate cancer in Sweden between 1992 and 2016. We found that men with lethal prostate cancer live longer and are older when they die today in comparison to men who died at the beginning of the study period. However, the proportion of men with distant metastases at diagnosis remains high, which is why early detection of lethal tumors is essential to reduce mortality.
Sections du résumé
Background
UNASSIGNED
Attempts to reduce prostate cancer (PC) mortality require an understanding of temporal changes in the characteristics of men with lethal PC.
Objective
UNASSIGNED
To describe the diagnostic characteristics of and time trends for a nationwide population-based cohort of Swedish men who died from PC between 1992 and 2016.
Design setting and participants
UNASSIGNED
Men with PC as the underlying cause of death from 1992 to 2016 according to the Swedish Cause of Death Register were included in the study. Characteristics at diagnosis were collected via links to other nationwide registries using personal identity numbers.
Outcome measurements and statistical analysis
UNASSIGNED
Data on disease duration, age at death, and risk category were analyzed. Missing data for risk categories for men with an early date of PC diagnosis were imputed according to the method of chained equations.
Results and limitations
UNASSIGNED
Between 1992 and 2016, age-standardized PC mortality decreased by 25%. Median PC disease duration increased from 3.3 yr (interquartile range [IQR] 1.6-6.3) to 5.9 yr (IQR 2.5-10.3) and the median age at death from PC increased from 78.9 yr (IQR 73.3-84.2) to 82.2 yr (IQR 75.2-87.5). The proportion of men with localized disease at diagnosis who died from PC increased from 34% to 48%, while the rate of distant metastases at diagnosis decreased from 56% to 42%. The rate of distant metastases at diagnosis was highest among the youngest men. Treatment trajectories could not be described owing to the large proportion of missing data before the start of registration in the National Prostate Cancer Registry.
Conclusion
UNASSIGNED
Age-standardized PC mortality has decreased substantially since 1992. However, there is still a high proportion of men who die from PC who had localized disease at diagnosis, which indicates that more attention is needed to identify the underlying causes to prevent disease progression. Since the proportion of men with distant metastases at diagnosis remains high, early detection of lethal tumors is essential to further reduce PC mortality.
Patient summary
UNASSIGNED
We investigated the characteristics of men who died from prostate cancer in Sweden between 1992 and 2016. We found that men with lethal prostate cancer live longer and are older when they die today in comparison to men who died at the beginning of the study period. However, the proportion of men with distant metastases at diagnosis remains high, which is why early detection of lethal tumors is essential to reduce mortality.
Identifiants
pubmed: 35813253
doi: 10.1016/j.euros.2022.05.003
pii: S2666-1683(22)00609-7
pmc: PMC9257655
doi:
Types de publication
Journal Article
Langues
eng
Pagination
81-87Informations de copyright
© 2022 The Author(s).
Références
Int J Epidemiol. 2013 Aug;42(4):956-67
pubmed: 22561842
Eur Urol. 2015 Nov;68(5):885-90
pubmed: 25791513
Int J Cancer. 2011 Oct 15;129(8):1881-8
pubmed: 21154740
Stat Med. 2021 Feb 28;40(5):1172-1188
pubmed: 33241594
Lancet Oncol. 2021 Sep;22(9):1240-1249
pubmed: 34391509
Eur Urol. 2020 Jan;77(1):38-52
pubmed: 31493960
Eur J Cancer. 2017 Oct;84:18-26
pubmed: 28779631
Eur Urol. 2012 Nov;62(5):745-52
pubmed: 22704366
N Engl J Med. 2015 Aug 20;373(8):737-46
pubmed: 26244877
Lancet. 2016 Mar 19;387(10024):1163-77
pubmed: 26719232
Scand J Urol Nephrol. 2011 Sep;45(4):226-32
pubmed: 21463227
Eur Urol. 2017 Jul;72(1):125-134
pubmed: 27481175
J Natl Compr Canc Netw. 2016 Jan;14(1):19-30
pubmed: 26733552
Lancet Oncol. 2015 Dec;16(16):1667-76
pubmed: 26563502
Lancet. 2014 Dec 6;384(9959):2027-35
pubmed: 25108889
N Engl J Med. 2016 Oct 13;375(15):1415-1424
pubmed: 27626136
Acta Oncol. 2015 Feb;54(2):158-63
pubmed: 25034349
Am J Epidemiol. 2021 Oct 1;190(10):2053-2063
pubmed: 34007984
J Natl Cancer Inst. 2014 Mar;106(3):dju007
pubmed: 24610909
Am J Surg Pathol. 2016 Feb;40(2):244-52
pubmed: 26492179
Eur Urol. 2015 Aug;68(2):207-13
pubmed: 25682340
Scand J Urol. 2014 Oct;48(5):426-35
pubmed: 24611795
N Engl J Med. 2017 Jul 27;377(4):352-360
pubmed: 28578607
Int J Cancer. 2015 Oct 1;137(7):1749-57
pubmed: 25821151